ad image

Hemophilia A

1 / 1
BioMarin Going for 2020 Approval of its Hemophilia A Gene Therapy
Drug Approval

BioMarin Going for 2020 Approval of its Hemophilia A Gene Therapy

Pharma's Almanac

PAO-M08-19-NI-026Aug 22, 2019
Bayer Statement on Voluntary Recall of Two Lots of Kogenate® FS Antihemophilic Factor (Recombinant) in the United States
Recall

Bayer Statement on Voluntary Recall of Two Lots of Kogenate® FS Antihemophilic Factor (Recombinant) in the United States

Nice Insight

PR-M07-19-NI-062Jul 24, 2019
Bayer Gets FDA Approval for Hemophilia A Drug
Drug Development

Bayer Gets FDA Approval for Hemophilia A Drug

Emilie Branch

Pharma's Almanac

PAO-M09-18-NI-006Sep 06, 2018
Sangamo Therapeutics
Clinical Trial

Sangamo Announces Positive Preliminary Data from the Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for Hemophilia A

Sangamo Therapeutics

PR-M08-18-NI-113Aug 29, 2018
Shire Submits IND for Hemophilia A Gene Therapy
Cell and Gene Therapy

Shire Submits IND for Hemophilia A Gene Therapy

Nigel Walker

Nice Insight

PAO-M07-17-NI-016Jul 13, 2017
1 / 1